Loading...
•
Mar 31
Vericel Q1 2025 Earnings Report
Estimated Revenue:$53.6M
+9.7% YoY
Estimated EPS:-$0.129
18.8% YoY
Key Takeaways
Vericel reported record first quarter MACI and total revenue, driven by continued strength in MACI Arthro launch. The company reaffirmed full-year revenue guidance and raised profitability guidance.
Total net revenue for the first quarter of 2025 was $52.6 million, an increase from $51.3 million in the prior year.
MACI net revenue grew by 15% to $46.3 million, representing a record first quarter for the product.
The company achieved a gross margin of 69% in the first quarter.
Vericel ended the quarter with approximately $162 million in cash, restricted cash, and investments, and no debt.
Vericel
Vericel
Vericel Revenue by Segment
Revenue by Segment
MACI Net Revenue
CapyFin.comEpicel Net Revenue
CapyFin.comNexoBrid Net Revenue
CapyFin.com Forward Guidance
Vericel reaffirmed full-year 2025 total revenue guidance with expected growth of 20% to 23% and raised full-year profitability guidance to a gross margin of 74% and adjusted EBITDA margin of 26%. Second quarter total revenue growth is expected to be 22% to 25%.
Positive Outlook
- Reaffirmed full-year total revenue growth guidance of 20% to 23%.
- Raised full-year profitability guidance to gross margin of 74%.
- Raised full-year profitability guidance to adjusted EBITDA margin of 26%.
- Expected second quarter total revenue growth of 22% to 25%.
- Company is well-positioned for continued high revenue and profit growth in 2025 and beyond.
Loading...
Key Statistics
Market Cap
$1.89B
P/E Ratio
146.73
Sector
N/A
Industry
N/A
52-Week High
$61.6
52-Week Low
$29.7
69%
$3.2M
$6.6M